The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001377325p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
17/09/2026
Date registered
Help: Date registered
17/11/2026
Date last updated
Help: Date last updated
17/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The feasibility of community-informed future food development using heart-healthy plant bioactives in older adults (CARDI-Boost Study)
Scientific title
The feasibility of community-informed future food development using heart-healthy plant bioactives in older adults (CARDI-Boost Study)
Additional trial identifiers [1] 318458 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Cardiovascular disease 343632 0
Obesity 343820 0
hypertension 344090 0
Coronary heart disease 344091 0
Condition category
Condition code
Cardiovascular 339745 339745 0 0
Diseases of the vasculature and circulation including the lymphatic system
Diet and Nutrition 339955 339955 0 0
Obesity
Cardiovascular 339956 339956 0 0
Hypertension
Cardiovascular 339957 339957 0 0
Coronary heart disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study is a single-arm, 4-week feasibility study designed to evaluate the acceptability, adherence, tolerability, retention, and protocol fidelity of daily consumption of CARDI-Boost in adults at increased cardiovascular risk.

CARDI-Boost will be formulated using whole-food ingredients such as spinach and broccoli (providing vitamin K1), cruciferous vegetables (providing glucosinolates), spinach and beetroot as a source of dietary nitrate and apples (providing flavonoids).
To achieve a nutrient-dense formulation, selected fruits and vegetables will be freeze-dried and blended into prototype-specific fruit and vegetable powder blends. These blends will be incorporated into the respective food prototypes to develop the CARDI-Boost products. Namely, whole food matrix will be used and no chemical extraction or fractionation will be applied, and no supplements will be used.

This unique blend of freeze-dried fruit and vegetable powders produced in the ECU Future
The Foods & Digital Gastronomy Laboratory (led by Food Scientist Dr. Liezhou Zhong and Dr. Diksha Chadha) will be adopted. Freeze-drying technology retains the initial color, aroma, and beneficial nutrients (heat-sensitive vitamins, antioxidants) due to low-temperature dehydration and processing of food products. This procedure removes close to 90% of a product's fresh water weight. For example, a serving size of spinach is 30 g and is reduced to 3 g of serving size, based on a 90% reduction of moisture, whilst preserving the nutrient profile. A combination of vegetables and fruits with an average (~80-92%) of weight is reduced when freeze-dried. All individuals involved in the development of prototypes have achieved formal training, including certification from Food Safe and the Food Handler Training Program conducted by Environmental Health Australia.

One CARDI-Boost serving size - as freeze-dried powder approximately 30g

CARDI Boost is designed to help close the gap between current fruit and vegetable intake recommended by the Australian Dietary Guidelines. Adults typically consume about 2.3 serves of vegetables and 1.4 serves of fruit per day, compared with recommendations of 5 serves of vegetables and 2 serves of fruit. (Fruit 1 serve =150g, vegetables 1 serve = 75g)

Each CARDI Boost serving is formulated to provide approximately:
1.5 vegetable servings (0.5 serves of cruciferous + 0.5 serves of spinach + 0.5 serves of other vegetables) and
0.5 fruit serves (apple and berries). Taken twice daily, this delivers 3 vegetable serves and 1 fruit serve, which directly matches the planned intake gap.

1.5 fresh veg serves (0.5 serves of cruciferous + 0.5 serves of spinach + 0.5 serves of other vegetables) (~120 g) + 0.5 fresh fruit serve (~75 g)—combined of
Twice daily = 3 veg serves + 1 fruit serve and Meets the planned target gap exactly

Freeze-drying removes (~85%) the initial weight therefore total of ~200g of fruits and vegetables. One serving of CARDI-Boost will be approximately 30 g of freeze-dried powder.

For the feasibility study, 30 g of CARDI-boost powder will be included in the food prototype, for example, cookie, gelato, snack ball, and sausage. But depending on the vegetable and fruit type and size included, the amounts of vitamin K1 and glucosinolates could vary, but for example, roughly every serve of 75 g contains 10-20 micrograms of vitamin K. Glucosinolates are a group of components, so they will not be measured individually. The study is not about how much of vitamin K or glucosinolates are helping to support the heart health. Previously our team has done much research on how vitamin K, glucosinolates, and flavonoids help for heart health; therefore, this study is to assess the feasibility of older adults adhering to a product like this with their daily lifestyle. But we will be doing the Nutrition profile and other laborotory requirements after developing the product.

Developing the final booster prototypes & sensory evaluation

Formulating CARDI Boost prototypes using vitamin K1 rich leafy greens (spinach, kale, broccoli), apple derived flavonoids (quercetin), and cruciferous bioactives. Prototypes will not have added sugar. Sweetness is derived from ingredients. After the freeze-drying process, fruits and vegetables become more concentrated, their flavour profile becomes more pronounced, and they end up being sweeter than fresh fruits. The prototypes will be optimised for sensory acceptability and analytically characterized for vitamin K1, glucosinolates, and flavonoids using accredited laboratory methods for basic nutrition profile, proximate analysis, HPLC or LC-MS/MS to assess vitamin K1, flavonoids and glucosinolates level.
Freeze drying technology at ECU’s Future Foods and Digital Gastronomy Lab will be used to preserve bioactives and other heat sensitive nutrients.
Final product Formats: CARDI-Boost Powder, cookie, gelato, snack ball and sausage prototypes will be developed based on talking to consumers from study 2 and previous data from our consumer reserach from our team. The CARDI-Boost powder will be able to be incorporated in any of the participant usual meals like soup or smoothies.
Processing Methods:
• Freeze-drying: involves freezing the food low temperatures (typically below -40°C), followed by vacuum drying, during which ice is removed by sublimation and the product is subsequently dried to remove residual moisture. Which can then be stored in airtight containers.
All individuals involved in the development of any food product has achieved formal training including certification from Food safe, Food handler training program conducted by Environmental health Australia.
Once the CARDI-Boost prototypes have been developed, participants will undergo an initial screening, including assessment of food allergies and dietary requirements. Eligible participants will then be invited to attend a second face-to-face session as part of Focus Group 2, comprising 6-8 participants. The 60-90-minute session will be held at the Royal Perth Hospital Research Foundation and will involve sensory evaluation and discussion of five CARDI-Boost food prototypes. The two focus groups are conducted to acceptability and to assess the best 3 food incorporated with CARDI-Boost powder. The 5 food items will be Cookie, Gelato, Sausage, CARDI-Boost incorporated soup, snack ball.
Participants will provide feedback on the prototypes, including taste, appearance, desirability, and suitability for inclusion in the daily diet.
They will be ranking the best acceptable 3 prototypes for the feasibility trial, which will be used for the feasibility trial.

Feasibility trial of consumption of CARDI-Boost over a period of 4 weeks.

The single-arm feasibility trial is designed to assess the acceptability, adherence, and tolerability of daily CARDI Boost consumption over four weeks in adults at increased cardiovascular risk. The study will follow the CONSORT extension for pilot and feasibility trials and will also obtain preliminary data on changes in dietary intake patterns. In addition, blood samples will be collected for biochemical assessment to refine the intervention protocol for a future definitive efficacy trial.

Participants will consume a combination of two CARDI-Boost products like a healthy cookie or dip made out of 30 g of freeze-dried fruit and veg powder for initial two weeks and CARDI-boost powder (30 g of freeze-dried fruit and vegetable powder) incorporated into foods like soups or smoothies twice a day for the final two weeks during the 4-week trial. Each portion will deliver: A defined amount of vitamin K1 rich leafy greens (e.g., kale/spinach), cruciferous vegetables (broccoli and kale) providing glucosinolates and apple as a quercetin rich flavonoid source. Participants will be asked to maintain their usual diet and physical activity, consume CARDI-Boost at a consistent time each day (e.g., with lunch or dinner) and record daily intake in a simple log (paper or digital). Products will be provided in single serve portions where possible or with clear portioning instructions depending on the feedback from the workshop. Storage instructions will be provided (e.g., store in cool, dry place; refrigerate after opening if applicable).

Participants will complete 2 clinic visits over a 4-week period, including screening/baseline (T0) and week four (T4) for 1-1.5 hours. All clinical visits will occur at the ECU Nutrition & Health Innovation Research Institute at the Royal Perth Hospital Research Foundation and Pathwest lab in Royal Perth reserach foundation.
The researcher (study lead) will be in touch over a call with the participants at end of each week(T1-T5) for 20-30 minutes to understand the adherence, tolerability, acceptability and other concerns.

During each visit, participants will complete (i) questionnaires, (ii) provide a venous blood sample for the assessment of various biomarkers (for Vitamin K1, and vitamin C). Each clinical visit is estimated to take a maximum of 2 hours.

The 2-week period between T0 and T2 will serve as a baseline to assess how everyone adapts to the concept of having two different CARDI-Boost prototypes a day while continuing their usual lifestyle (e.g. diet, exercise, medication) influencing markers of cardiometabolic health. Will also assess acceptability, adherence, and tolerability of daily CARDI-Boost consumption.
Immediately after T2, all participants will be required to consume twice daily CARDI-Boost powder which could be incorporated into their food like soups or smoothies for the final 2 weeks.


Data collection schedule will be as below
• Week T0:
o Consent and eligibility confirmation
o Patient information
o Baseline food diary instructions
o CARDI-Boost product allocation and consumption instructions
• Weeks T1–T3:
o Collection of adherence logs- weekly follow up call assessing count of unused portions, gastrointestinal tolerability.
• Week T4:
o Behavioural acceptance digital questionnaire (Attachment 07- post-trial questionnaire) and collection of blood samples for biochemical assessment.
o Return of remaining product

CARDI-Boost can be provided in two separate deliveries (once a fortnight) to ensure adequate storage space in participants freezers. Participants will have their final clinical visit 4 weeks later, after 28 days of daily CARDI-Boost consumption (T4). There will be no restriction in taking their usual medications or diet.


Participants will attend two clinic visits at baseline (T0) and week 4 (T4), where questionnaires, and fasting blood samples will be collected. Weekly telephone follow-up calls will be conducted to assess adherence, acceptability, tolerability, gastrointestinal symptoms, and any participant concerns. Feasibility outcomes include adherence measured through daily consumption logs and unused product counts, acceptability assessed using a 5-item Likert-scale questionnaire, tolerability assessed through weekly gastrointestinal symptom monitoring, retention.. Fasting blood samples collected at T0 and T4 will be analysed for blood lipids, glucose, vitamin K markers (ucOC/OC), and vitamin C concentrations. The findings will inform the feasibility and optimisation of CARDI-Boost for a future definitive efficacy trial.
Intervention code [1] 335369 0
Treatment: Other
Description of the comparator or control
No- control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346917 0
Adherence: Adherence will be defined as the proportion of prescribed intervention days on which the participant completes the prescribed intervention. Adherence will be calculated as the number of days on which the intervention was completed divided by the total number of prescribed intervention days, expressed as a percentage.
Timepoint [1] 346917 0
Weekly during the 4 weeks intervention
Primary outcome [2] 346918 0
Acceptability
Timepoint [2] 346918 0
End of 4 weeks of intervention (weeks post-intervention commencement,)
Primary outcome [3] 346919 0
Tolerability
Timepoint [3] 346919 0
Weekly during the 4-week intervention
Secondary outcome [1] 468137 0
vitamin K markers ucOC/OC
Timepoint [1] 468137 0
Blood tests were conducted one week prior to the study start date and blood tests were conducted at the end of the 4-week intervention period.
Secondary outcome [2] 469047 0
Online interview sheet
Timepoint [2] 469047 0
End of 4 weeks/post-trial after the biochemical assessment to assess the general efficay of the trial.
Secondary outcome [3] 469048 0
Total Lipids
Timepoint [3] 469048 0
blood tests conducted one week prior to the study start date and at the end of the 4-week intervention period.
Secondary outcome [4] 469050 0
HBA1c
Timepoint [4] 469050 0
Blood tests conducted at the end of the 4-week intervention period.
Secondary outcome [5] 469051 0
Vitamin C
Timepoint [5] 469051 0
Blood tests conducted at the end of the 4-week intervention period.

Eligibility
Key inclusion criteria
Adults 50–85 years, one or more cardiovascular risk factors (hypertension, hyperlipidaemia, diabetes mellitus, obesity, or family history of CVD), residing in the local metropolitan area, able to provide informed consent and willing to consume CARDI-Boost daily.
Minimum age
50 Years
Maximum age
85 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Major cardiovascular events (myocardial infarction, stroke, coronary revascularisation) within the past 6 months because they could have some food restrictions and special diet.
End stage renal disease patients will also have diet restrictions; therefore, we cannot include them.
Current use of warfarin or other vitamin K antagonists since it will make a difference when we measure vitamin K levels in blood.
Known allergy to cruciferous vegetables or apples and known allergies to dairy and nuts, as our ingredients mainly will have cruciferous vegetables and apples. Also could include nuts and dairy in some products.
Cognitive impairment limiting participation—The trial needs feedback about the food product developed in respect to acceptability and tolerability; therefore, we need participants who can themelves assess that.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
A sample of 19 participants, consistent with feasibility and data saturation and to small sample feasibility trials. This sample size will provide sufficient information to identify potential issues with the intervention or study procedures.

This is a feasibility study and not the RCT. SO participants will be recruited via flyers and posters in community centres, cardiac rehabilitation programs, and primary care clinics; email invitations and social media posts via university and community health organisations; and snowball sampling through existing research databases and cardiovascular prevention programs. Interested individuals will be screened for eligibility according to inclusion criteria defined above and provided with a Participant Information Sheet and Digital Consent Form.

Participants will be recruited randomly via flyers and posters in community centers, cardiac rehabilitation programs, and primary care clinics; email invitations and social media posts via university and community health organisations with their consent.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 323042 0
University
Name [1] 323042 0
Edith Cowan University
Country [1] 323042 0
Australia
Funding source category [2] 323047 0
Charities/Societies/Foundations
Name [2] 323047 0
Heart foundation future leader fellowship
Country [2] 323047 0
Australia
Primary sponsor type
University
Name
Edith Cowan University
Address
Country
Australia
Secondary sponsor category [1] 325986 0
None
Name [1] 325986 0
Address [1] 325986 0
Country [1] 325986 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321446 0
Edith Cowan University Human Research Ethics Committee
Ethics committee address [1] 321446 0
Ethics committee country [1] 321446 0
Australia
Date submitted for ethics approval [1] 321446 0
17/09/2026
Approval date [1] 321446 0
Ethics approval number [1] 321446 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153750 0
Mrs Kuhanneya Nisanthan
Address 153750 0
Royal Perth Reseach Foundation, 50 Murray Street Mall, Perth 6000 WA
Country 153750 0
Australia
Phone 153750 0
+61 478085838
Fax 153750 0
Email 153750 0
Contact person for public queries
Name 153751 0
Kuhanneya Nisanthan
Address 153751 0
Royal Perth Reseach Foundation, 50 Murray Street Mall, Perth 6000 WA
Country 153751 0
Australia
Phone 153751 0
+61 478085838
Fax 153751 0
Email 153751 0
Contact person for scientific queries
Name 153752 0
Kuhanneya Nisanthan
Address 153752 0
Royal Perth Reseach Foundation, 50 Murray Street Mall, Perth 6000 WA
Country 153752 0
Australia
Phone 153752 0
+61 478085838
Fax 153752 0
Email 153752 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: In compliance with ethics, data from this study will not be shared.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.